Innoviva (INVA)

Executive Summary

Innoviva, Inc. is a biopharmaceutical company with a unique hybrid business model that combines stable royalty revenues from partnered respiratory medicines (e.g., Relvar/Breo Ellipta, Anoro) with strategic investment in a novel pipeline of infectious disease and oncology therapeutics. The royalty stream provides predictable cash flows, funding the development of high-potential assets through its subsidiary. In 2025, the company generated approximately $300 million in royalty revenue, ensuring financial stability while pursuing growth opportunities. The pipeline includes two key clinical-stage programs: sulbactam-durlobactam for Acinetobacter baumannii infections (Phase 1 initiating in Q4 2026) and eravacycline for complicated intra-abdominal infections (Phase 2 ongoing). Additionally, a Phase 2 trial for Mycobacterium abscessus pulmonary disease is set to begin in April 2027. These programs target unmet medical needs in antibiotic resistance. With a strong balance sheet and consistent cash flows, Innoviva is well-positioned to advance its pipeline while maintaining shareholder returns.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Trial for Sulbactam-Durlobactam in ABC Infections90% success
• Q2 2027Initiation of Phase 2 Trial for Combination Regimen in Mycobacterium Abscessus Pulmonary Disease85% success